Proceedings of the National Academy of Sciences · 1972 · 319 citations · 14 references
Life SciencesCancer BiologyImmunologyCancer ImmunologyMonoclonal AntibodiesTumor ImmunologyCancer ImmunotherapyHistocompatibility AntigensImmunotherapy For Solid TumorsTumor AntigensTumor-associated AntigensCancer AntigensImmunogenicity Of Tumor AntigensTherapeutic Cancer ImmunizationTumor Antibody ResponsesTumor Antigen ImmunogenicityTumor Antigen RecognitionTumor Antigen VaccinesTumor Immunogenicity
BALB/c mice immunized with myeloma proteins 315 or 460 made antibodies to the individually specific ("idiotypic") determinants of these proteins and suppressed growth of the corresponding transplanted tumor cells (MOPC-315 or MOPC-460). Stable, variant MOPC-315 tumors that produce only the light chain of protein 315 grew in several of the mice immunized with this protein, probably because the anti-idiotypic immune response selects against those myeloma cells that form the intact myeloma protein.
14